Changes to our company portfolio – MSD and Organon & Co. read more
Changes to our company portfolio
Please note that as of June 3rd 2021, MSD completed the spin-off of products from its women’s health, legacy brands, and biosimilars franchises into the new independent, publicly traded company Organon & Co.
For information on former MSD products now transferred to Organon & Co. please visit their website.
MSD UK customer services
0208 1548001
(During public holidays please contact our UK switchboard on 0208 1548000).
Emergency patient supply order form
Please click here to download an emergency patient supply order form (for use by UK healthcare professionals only).
Supply Status
|
Product Description
|
Supply Status
|
Estimated Resupply Date
|
|
ZERBAXA®
1 g/0.5 g powder for concentrate for solution for infusion
|
Out of Stock
|
2022
|
|
EMEND®
125 mg powder for oral suspension
|
Intermittent Supply
|
End July 2021
|
Notifications
Class 2 Medicines Recall: Merck Sharp & Dohme Limited, Zerbaxa 1g/0.5g Powder for Concentrate for Solution for Infusion, EL (20)A/60
Information can be found here: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-merck-sharp-and-dohme-limited-zerbaxa-1g-slash-0-dot-5g-powder-for-concentrate-for-solution-for-infusion-el-20-a-slash-60
Zoely® 2.5 mg/1.5 mg film-coated tablets
As of 1st July 2020, Zoely® 2.5 mg/1.5 mg film-coated tablets is no longer supplied by MSD - refer to Theramex for more information.
COVID-19
We continue to track the COVID-19 outbreak closely and are focused on the safety of our employees and their families, continuity of supply and clinical trials, and supporting communities affected by this outbreak. Our thoughts are with the people of all affected areas.
Information about Esmeron® (rocuronium bromide) 10 mg/ml solution for injection
In relation to the COVID 19 crisis, we are experiencing a substantial increase in demand for our product Esmeron globally and the Company is actively engaged in increasing supply. To help the supply of rocuronium bromide to the UK market, a quantity of Esmeron which was packaged for Australia has been made available to the UK, as an interim measure.
The Medicines and Healthcare Regulatory Agency (MHRA) have approved the use of this supply for the UK.
The details of the batches that will be supplied are detailed below:
|
Batch number
|
Expiry date
|
|
T011923
|
Feb 2023
|
|
T011924
|
Feb 2023
|
|
T012129
|
Feb 2023
|
|
T012763
|
Feb 2023
|
|
T012764
|
Feb 2023
|
|
T014251
|
Feb 2023
|
|
T014929
|
Mar 2023
|
|
T014958
|
Mar 2023
|
|
U003785
|
Nov 2023
|
A letter has been distributed to describe the differences in the packaging and that a PIL is not included in the pack, this letter can be found here.
Discontinuations
- Product Description
- Rebetol 200 mg hard capsules
This page is intended for use by UK healthcare professionals only. Trademarks appearing on this website are owned, licensed to, promoted or distributed by Merck & Co., Inc., Kenilworth, NJ, USA, its subsidiaries or affiliates, except as noted.
Job code: GB-NON-04560Date of preparation: June 2021